Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer

Autor:	Maryam Fallahpoor, Hojjat Ahmadzadehfar, Nasim Vahidfar, Saeed Farzanehfar, Ghasemali Divband
Rok vydání:	2019
Předmět:	medicine.drug_class business.industry Health Toxicology and Mutagenesis Public Health Environmental and Occupational Health urologic and male genital diseases Monoclonal antibody medicine.disease Pollution Analytical Chemistry Prostate cancer Nuclear Energy and Engineering medicine Cancer research Dosimetry Radiology Nuclear Medicine and imaging business Spectroscopy Membrane antigen
Zdroj:	Journal of Radioanalytical and Nuclear Chemistry. 322:237-248
ISSN:	1588-2780 0236-5731
DOI:	10.1007/s10967-019-06800-6
Popis:	Many efforts have been made to introduce an appropriate radiopharmaceutical as a theranostic agent for metastatic castration-resistant prostate cancer. Prostate-specific membrane antigen (PSMA) is expressed in most types of prostate cancer (PCa), with only 5–10% of primary PCa lesions being PSMA-negative. When radiolabeled, PSMA tracers show outstanding features in terms of their theranostic properties. In this study, we discuss the pharmacological and physical characteristics of various radiopharmaceuticals used for the theranostic treatment of PCa. This review aims to outline the developments from the first radiopharmaceuticals PCa, including monoclonal antibodies, to the final gold standard in PSMA-based theranostics.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::647ecea339a6846d38fa6c22d2cda777 https://doi.org/10.1007/s10967-019-06800-6 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.